Oncolytics Biotech, a biotechnology company, has reported positive preliminary results from its US Phase II trial of Reolysin, intravenously administered in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lung (SCCLC).

Patients with metastatic stage IIIB, stage IV, or recurrent squamous cell carcinoma of the lung, who are chemotherapy naïve for their metastatic or recurrent cancer, were treated in the first stage of two stage study.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

If four or more patients demonstrated a partial response (PR) or better, the study would proceed to the second stage, with up to 55 patients being treated in the entire study.

Oncolytics president and CEO Dr Brad Thompson said the preliminary results are encouraging and further support the decision to undergo the study.

"Oncolytics Phase II program continues to grow and now includes randomised trials in six separate indications," Thompson said.

See Also:

The endpoint was met after 15 evaluable patients were enrolled, and the company is proceeding with the second stage of the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Five of 15 patients showed PR, four confirmed, one unconfirmed, and an additional eight patients had stable disease, for a disease control rate of 87%.

The primary objective of the Phase II trial is to assess the antitumor effect of the treatment regimen in the study population in terms of objective response rates.

The secondary objectives include the assessment of progression-free survival and overall survival for the treatment regimen in the study population, to determine the proportion of patients receiving the above treatment who are alive and free of disease progression at six months and to assess the safety and tolerability of the treatment regimen in the study population.